| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/10/2003 | US20030068315 The polysaccharides in the complexes form an envelope which protects and carries immunoglobulins allowing their systemic absorption through gastric and mucosal membrane; polysacchride and immunoglobulins are bonded by ionic bonds |
| 04/10/2003 | US20030068299 Administering promoter of T-cell expansion and inducer of CD40 stimulation in synergistically effective amounts to treat or prevent pathologic state in mammal; cancer therapy |
| 04/10/2003 | US20030068279 Dispersible pharmaceutical-based dry powder composition comprising a therapeutically effective amount of pharmaceutical in combination with a pharmaceutically acceptable carrier |
| 04/10/2003 | CA2776522A1 Development of a preventive vaccine for filovirus infection in primates |
| 04/10/2003 | CA2776391A1 Development of a preventive vaccine for filovirus infection in primates |
| 04/10/2003 | CA2776272A1 Development of a preventive vaccine for filovirus infection in primates |
| 04/10/2003 | CA2466020A1 Rsv gene expression vaccine |
| 04/10/2003 | CA2463404A1 Fragements of heat shock proteins and their use |
| 04/10/2003 | CA2462790A1 Ul16 binding protein 4 |
| 04/10/2003 | CA2462682A1 The use of gammaglobulin for the treatment of immune-mediated diseases |
| 04/10/2003 | CA2462646A1 Adjuvanted meningococcus compositions |
| 04/10/2003 | CA2462602A1 Double stranded rna as an adjuvant in vaccine compositions |
| 04/10/2003 | CA2462427A1 Treatment of hepatitis b virus infection with human monoclonal antibodies |
| 04/10/2003 | CA2462424A1 A novel g protein-coupled receptor, gave 10 |
| 04/10/2003 | CA2462259A1 Mammalian cell-infecting virus vector encoding epitope-bound .beta.2m and utilization thereof |
| 04/10/2003 | CA2462162A1 Identification of new cd8 epitopes from hiv-1 proteins with therapeuticaal and vaccinal properties against hiv infections |
| 04/10/2003 | CA2461924A1 Vaccine |
| 04/10/2003 | CA2461877A1 Method of treatment using ligand-immunogen conjugates |
| 04/10/2003 | CA2461254A1 Polypeptides derived from inducible hsp70 and pharmaceutical compositions containing the same |
| 04/10/2003 | CA2460917A1 Human tissue factor antibodies |
| 04/10/2003 | CA2460916A1 Methods and compositions for modulating interleukin-21 receptor activity |
| 04/10/2003 | CA2438330A1 A method for the early detection of cancer |
| 04/09/2003 | EP1300468A2 TRNA synthetase |
| 04/09/2003 | EP1300419A1 Antibody of human origin for inhibiting thrombocyte aggregation |
| 04/09/2003 | EP1300157A1 Attenuated mutant newcastle disease virus strains for in ovo vaccination, method for preparing and their use |
| 04/09/2003 | EP1300156A2 Otitis media vaccine |
| 04/09/2003 | EP1300146A1 Pharmaceutical composition for the treatment of animal mammary tumors |
| 04/09/2003 | EP1299727A2 Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers |
| 04/09/2003 | EP1299549A1 Helicobacter pylori heptosyltransferase polynucleotides and polypeptides |
| 04/09/2003 | EP1299544A2 Fimh adhesin proteins and methods of use |
| 04/09/2003 | EP1299542A2 Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
| 04/09/2003 | EP1299536A1 Novel alpha-catenin expressed in heart and testis |
| 04/09/2003 | EP1299527A2 Helicobacter dd-heptosyltransferase |
| 04/09/2003 | EP1299524A1 Human myeloma cell line |
| 04/09/2003 | EP1299523A2 Method for the modification of biological cells |
| 04/09/2003 | EP1299522A2 Alteration of cell membrane |
| 04/09/2003 | EP1299421A2 Antibodies to human mcp-1 |
| 04/09/2003 | EP1299420A2 Composition for pharmaceutical and cosmetic products |
| 04/09/2003 | EP1299417A2 Compositions and methods for the therapy and diagnosis of breast cancer |
| 04/09/2003 | EP1299130A2 A method of treating and preventing infectious diseases |
| 04/09/2003 | EP1299128A2 Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination |
| 04/09/2003 | EP1299118A2 Production and use of derivatized homoserine lactones |
| 04/09/2003 | EP1299117A2 Vaccine against helicobacter pylori |
| 04/09/2003 | EP1299115A2 Methods and compositions for developing spore display systems for medicinal and industrial applications |
| 04/09/2003 | EP1299087A1 Microspheres and adjuvants for dna vaccine delivery |
| 04/09/2003 | EP1299032A1 DNA encoding human serine protease D-G |
| 04/09/2003 | EP1141487B1 System for predicting compaction performance |
| 04/09/2003 | EP0827396B1 Production scale method of forming microparticles |
| 04/09/2003 | EP0825998B1 Preparation of immunoglobulin |
| 04/09/2003 | EP0804552B1 Redirection of cellular immunity by receptor chimeras |
| 04/09/2003 | EP0784685B1 Chicken anemia virus mutants and vaccines and uses based on the viral proteins vp1, vp2 and vp3 or sequences of that virus coding therefor |
| 04/09/2003 | EP0758384B1 Leishmania major protein, nucleic acid coding therefor, and uses thereof |
| 04/09/2003 | EP0725824B1 Immunodominant human t-cell epitopes of hepatitis c virus |
| 04/09/2003 | CN1409765A Prevention of myocarditis, abortion and intrauterine infection associated with procine circovirus 2 |
| 04/09/2003 | CN1409764A Pseudomonas aeruginosa antigens |
| 04/09/2003 | CN1409758A Stabilizing diluent for polypeptides and antigens |
| 04/09/2003 | CN1409726A Type I cytokine receptor TCCR |
| 04/09/2003 | CN1409725A Peptide minics of conserved gonococcal epitopes and methods and compositions using them |
| 04/09/2003 | CN1409722A Antagonists of BMP and TGF beta signalling pathway |
| 04/09/2003 | CN1409720A Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| 04/09/2003 | CN1409641A DNA- vaccine based on constructs drived from genomes of human and animal pathogens |
| 04/09/2003 | CN1409639A TNF-alpha antagonist and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder |
| 04/09/2003 | CN1408880A Detecting and trapping receptor 3 monoclonal antibody, hybrid tumor for producing said antibody and its use |
| 04/09/2003 | CN1408874A Procaryotic cell in vivo antibody library construction screening and optimizing of antibody and use |
| 04/09/2003 | CN1408851A Non-coding region and P.M gene sequence and vector construction of long-47 measles virus |
| 04/09/2003 | CN1408436A Recombinant Borrel virus combined vaccine |
| 04/09/2003 | CN1408435A Method for medicinal matter for nose |
| 04/09/2003 | CN1408434A Polypeptide and DNA combined vaccine for resisting animal's foot-and-mouth disease and its preparing method |
| 04/09/2003 | CN1408433A AIDs recombination epitope vaccine and its preparing method |
| 04/09/2003 | CN1104907C Vibrio cholerae 01 (CVD111) and Non-01 (CVD112 and CVD112 RM) serogroup vaccine strain and methods of making same |
| 04/08/2003 | USRE38071 Method for treating infectious respiratory diseases |
| 04/08/2003 | US6545142 Primers; nucleotide sequence |
| 04/08/2003 | US6545137 Autoimmune diseases; antiinflammatory agents; viricides; antidiabetic agents; binding to low density lipoproteins |
| 04/08/2003 | US6545133 Purification; complexing with oligonucleotides; separation |
| 04/08/2003 | US6545127 Catalytically active recombinant memapsin and methods of use thereof |
| 04/08/2003 | US6544952 Synthesis of glycoconjugates of the globo-H epitope and uses thereof |
| 04/08/2003 | US6544785 Helper viruses; genetic engineering |
| 04/08/2003 | US6544784 Multiple-tumor aberrant growth genes |
| 04/08/2003 | US6544780 Adenovirus vector with multiple expression cassettes |
| 04/08/2003 | US6544769 Compostions comprising viruses and methods for concentrating virus preparations |
| 04/08/2003 | US6544759 Polynucleotides encoding a novel growth factor which acts through ErbB-4 kinase receptor tyrosine |
| 04/08/2003 | US6544758 Methods for expressing endostatin protein |
| 04/08/2003 | US6544757 Genetic engineering; hepatitis virus |
| 04/08/2003 | US6544752 Anigenically-marked non-infectious retrovirus-like particles |
| 04/08/2003 | US6544728 Methods and kits for diagnosing human immunodeficiency virus type 2 (HIV-2), proteins of HIV-2, and vaccinating agents for HIV-2 |
| 04/08/2003 | US6544563 Synergistic mixture of arginine and nitric oxide synthase |
| 04/08/2003 | US6544549 Multilamellar coalescence vesicles (MLCV) containing biologically active compounds |
| 04/08/2003 | US6544529 Isolated strains of Staphylococcus aureus and vaccines manufactured therefrom |
| 04/08/2003 | US6544528 For protecting cats from infection by a broad range of feline leukemia virus |
| 04/08/2003 | US6544527 Non-infectious, immunogenic, human immunodeficiency virus-like particles devoid of long terminal repeats and a functional pol coding region |
| 04/08/2003 | US6544526 For immunization of horses |
| 04/08/2003 | US6544522 Fusion proteins of mycobacterium tuberculosis antigens and their uses |
| 04/08/2003 | US6544521 Immunoreactive peptide CTL epitopes of human cytomegalovirus pp150 |
| 04/08/2003 | US6544520 Isolated, purified peptide that inhibits hepatitis B virus assembly by binding to the core antigen of hepatitis B virus and preventing association |
| 04/08/2003 | US6544519 Polypeptide originating in haemophilus paragallinarum and process for producing the same |
| 04/08/2003 | US6544518 Vaccines |
| 04/08/2003 | US6544517 Outer membrane protein of Ehrlichia canis and Ehrlichia chaffeensis |
| 04/08/2003 | US6544516 Treating with anitbodies for bactericidal activity against enterococci |
| 04/08/2003 | US6544514 Compositions comprising, as the main ingredient, allogenic activated-C4+ cells and method for producing and using the same |
| 04/08/2003 | US6544506 Veto cells effective in preventing graft rejection and devoid of graft versus host potential |